Table 1.
Compound | Study | Results | Authors |
---|---|---|---|
Estrogen | A retrospective population study to analyze the incidence of BPPV and protective factors against it. | The incidence of BPPV is significantly lower in estrogen-treated patients due to menopausal syndromes. | Liu et al., (2017). |
Estrogen + Progesterone | A prospective study of 10 female patients diagnosed with BPPV and treated with HRT. | The cessation of treatment with oral contraceptives keeps vertigo under control. | Giacomini et al., (2006). |
Vitamin D | A longitudinal study of patients with low levels of vitamin D (<20 ng/mL), 27 treated/27 not treated with 50.000 IU cholecalciferol weekly + maneuvers for two months. | The group treated with vitamin D decreased BPPV episodes. They remained stable and unchanged during the study period compared to the untreated group. | Sheikhzadeh et al., (2016). |
Vitamin D | A prospective study of 40 patients with BPPV; 16 out of them were treated with vitamin D due to their low levels (unspecified dose). | Supplementation decreased BPPV episodes, but the results were not statistically significant. | Cupido et al., (2018). |
Bisphosphonates Raloxifene Calcitonin Teriparatide |
A retrospective study of osteoporosis treated in 260 women with and BPPV, aged 51–80 years. | A negative association between BPPV and treated osteoporosis in women aged 51–60 years. | Mikulec et al., 2009. |
Methylprednisolone | A pilot study of 9 patients with persistent posterior canal BPPV treated intratympanically (two weekly doses of 0.3–0.4 mg/mL to 40 mg/mL) before repeating repositioning procedures. | 7 out of 9 patients were relieved of their symptoms and did not exhibit positional nystagmus after 1 or 2 repositioning maneuvers. | Perez et al., (2016). |
Dexamethasone | 2 cases with intractable posterior BPPV treated with 3.3 mg in 1 ml solution | Relief of symptoms and absence of nystagmus in positional maneuvers. | Kelkar et al., (2018). |